, HESI Pharmacology V2 Exam 2026/2027: Elsevier Evolve
NCSBN Clinical Judgment Model-Aligned Study Set with
Questions & Rationales - 135 Questions
Section 1: Pharmacokinetics and Pharmacodynamics (Questions 1-10)
1 A drug exhibits a volume of distribution (Vd) of 5 L and a clearance (Cl) of 1 L/hr. Which of the following best
describes the expected half-life (t½) and the implication for dosing frequency?
A) t½ 3.5 hr; requires frequent dosing to maintain steady state.
B) t½ 0.5 hr; requires continuous infusion.
C) t½ 17 hr; allows once-daily dosing.
D) t½ 35 hr; risk of accumulation with daily dosing.
Answer: A
Rationale: Half-life = 0.693 × Vd / Cl = 0.693 × 5 L / 1 L/hr "H 3.47 hr. A short half-life necessitates frequent dosing
to maintain therapeutic levels. Option B miscalculates (Cl/Vd), C and D use incorrect multipliers.
2 A novel drug is a weak base with pKa = 7.4. It is administered orally. Which of the following conditions would
MOST significantly enhance its absorption in the small intestine (pH 6.0)?
A) Concurrent administration of a proton pump inhibitor.
B) Formulation as a delayed-release enteric-coated tablet.
C) Coadministration with a high-fat meal that increases bile secretion.
D) Administration via sublingual route to avoid first-pass metabolism.
Answer: A
Rationale: At small intestinal pH 6.0, the drug (pKa 7.4) is predominantly ionized (weak base, pH < pKa). Raising
gastric pH with a PPI reduces ionization in the stomach but does not affect small intestine absorption; however, a
PPI increases gastric pH, which may reduce degradation and enhance dissolution. Option B delays release but not
absorption per se; C increases solubility of lipophilic drugs but not ionization-dependent absorption; D bypasses
first-pass but is not about absorption enhancement in the small intestine.
3 A drug follows Michaelis-Menten kinetics. At a dose of 100 mg, the steady-state concentration (Css) is 10
mg/L. When the dose is doubled to 200 mg, Css increases to 30 mg/L. Which of the following is the most likely
explanation?
A) The drug exhibits linear pharmacokinetics within this dose range.
B) The drug has a high extraction ratio and is flow-limited.
C) The drug's elimination pathway is saturable at the higher dose.
D) The drug's volume of distribution decreased due to dose-dependent protein binding.
Answer: C
Rationale: In Michaelis-Menten kinetics, when the dose approaches or exceeds the enzyme capacity (Km), Css
increases more than proportionally. Here, doubling the dose triples Css, indicating saturation. Option A is incorrect
because linear kinetics would show proportional increase; B is unrelated; D could cause a decrease in Vd but would
increase Css less than proportionally if binding is saturable, not more.
4 Which of the following best explains why a drug that is a substrate of CYP3A4 and P-glycoprotein (P-gp)
exhibits higher oral bioavailability when coadministered with grapefruit juice?
A) Grapefruit juice increases gastric pH, enhancing dissolution.
,B) Grapefruit juice inhibits intestinal CYP3A4 and P-gp, reducing first-pass metabolism and efflux.
C) Grapefruit juice induces hepatic CYP3A4, increasing clearance.
D) Grapefruit juice chelates the drug, forming a more absorbable complex.
Answer: B
Rationale: Grapefruit juice irreversibly inhibits intestinal CYP3A4 and also inhibits P-gp, leading to increased
absorption and reduced first-pass metabolism, thus increasing oral bioavailability. Option A is false; C is opposite
(induction would decrease bioavailability); D is not a known mechanism.
5 Two drugs, A and B, are both agonists at the same receptor. Drug A has an EC50 of 10 nM and produces a
maximal response (Emax) of 80% of the tissue maximum. Drug B has an EC50 of 100 nM and an Emax of
100%. Which of the following statements is correct?
A) Drug A is more potent and more efficacious than Drug B.
B) Drug A is more potent but less efficacious than Drug B.
C) Drug B is more potent and more efficacious than Drug A.
D) Drug B is more potent but less efficacious than Drug A.
Answer: B
Rationale: Potency is inversely related to EC50: lower EC50 = higher potency. Drug A (EC50=10 nM) is more
potent than Drug B (100 nM). Efficacy refers to maximal response: Drug B produces 100% (full agonist) vs Drug
A produces 80% (partial agonist). Thus A is more potent but less efficacious.
6 A drug is 99% bound to plasma albumin. Which of the following scenarios would MOST significantly increase
the free (unbound) fraction of the drug?
A) Hypoalbuminemia (albumin concentration reduced by 50%).
B) Coadministration with another drug that is 99% bound to albumin and has the same binding site.
C) Renal impairment that reduces drug clearance.
D) Hepatic enzyme induction increasing drug metabolism.
Answer: B
Rationale: Displacement from binding sites by a competing drug can significantly increase free fraction even with
normal albumin levels. Option A (hypoalbuminemia) reduces total binding capacity but for a highly bound drug
(99%), a 50% reduction in albumin might only increase free fraction from 1% to ~2% (still small). B can cause a
larger relative increase if the competitor has high affinity and concentration. C and D affect total drug concentration
but not directly binding fraction.
7 A drug has a low extraction ratio (E < 0.3) and is primarily eliminated by hepatic metabolism. Which of the
following best describes the effect of a decrease in hepatic blood flow on its clearance and half-life?
A) Clearance decreases, half-life increases.
B) Clearance unchanged, half-life unchanged.
C) Clearance increases, half-life decreases.
D) Clearance decreases, half-life unchanged.
Answer: B
Rationale: For low extraction ratio drugs, clearance is primarily dependent on intrinsic clearance (enzyme activity)
and protein binding, not hepatic blood flow. Therefore, a decrease in blood flow does not significantly alter
clearance. Half-life (t½ = 0.693 × Vd/Cl) remains unchanged if Cl and Vd are unchanged. Options A, C, D
incorrectly assume flow-dependence.
, 8 A drug follows a two-compartment model. After an IV bolus, the plasma concentration-time curve shows a
rapid initial decline ( phase) followed by a slower terminal phase ( phase). Which of the following parameters is
MOST directly associated with the phase half-life?
A) Distribution clearance (ClD)
B) Volume of the central compartment (Vc)
C) Elimination clearance (ClE) and volume of distribution at steady state (Vss)
D) Absorption rate constant (ka)
Answer: C
Rationale: In a two-compartment model, the terminal (²) half-life is determined by elimination clearance and the
overall volume of distribution (Vss or V). The phase reflects distribution. Option A relates to intercompartmental
clearance; B is part of distribution; D is irrelevant for IV bolus.
9 A drug is a weak acid with pKa = 4.4. Which of the following statements about its renal excretion is correct?
A) At urine pH 5.0, the drug is predominantly ionized and will be reabsorbed.
B) At urine pH 8.0, the drug is predominantly ionized and will be excreted more rapidly.
C) Alkalinization of urine will decrease the rate of excretion.
D) Acidification of urine will increase the rate of excretion.
Answer: B
Rationale: Weak acids are more ionized in alkaline pH (pH > pKa). At pH 8.0, the drug (pKa 4.4) is >99.9%
ionized, reducing reabsorption and enhancing excretion. Option A is incorrect because at pH 5.0 (below pKa), it is
mostly unionized and reabsorbed. C is opposite (alkalinization increases excretion). D is opposite (acidification
decreases excretion).
10 A drug has a therapeutic index (TI) of 2. Which of the following interpretations is correct?
A) The drug is safe with a wide margin between effective and toxic doses.
B) The median toxic dose (TD50) is twice the median effective dose (ED50).
C) The ED50 is twice the TD50.
D) The drug requires therapeutic drug monitoring due to narrow safety margin.
Answer: B
Rationale: Therapeutic index = TD50/ED50. A TI of 2 means the toxic dose is only twice the effective dose,
indicating a narrow margin. Option A is false (wide margin would be >10). C is reversed. D is a reasonable clinical
implication but not the direct definition; the question asks for interpretation of the numerical value, so B is the
precise definition.
Section 2: Autonomic Nervous System Drugs (Questions 11-25)
11 A patient with a history of hypertension and benign prostatic hyperplasia is prescribed tamsulosin. Which
receptor selectivity best explains the therapeutic effect on urinary symptoms while minimizing impact on blood
pressure?
A) Selective 1A-adrenoceptor antagonism
B) Selective 1B-adrenoceptor antagonism
C) Nonselective 1-adrenoceptor antagonism
D) 2-adrenoceptor agonism
Answer: A
Rationale: Tamsulosin is selective for ±1A-adrenoceptors, which predominate in the prostate and bladder neck,
allowing relief of urinary obstruction with less effect on vascular 1B-receptors, thus minimizing hypotension.
NCSBN Clinical Judgment Model-Aligned Study Set with
Questions & Rationales - 135 Questions
Section 1: Pharmacokinetics and Pharmacodynamics (Questions 1-10)
1 A drug exhibits a volume of distribution (Vd) of 5 L and a clearance (Cl) of 1 L/hr. Which of the following best
describes the expected half-life (t½) and the implication for dosing frequency?
A) t½ 3.5 hr; requires frequent dosing to maintain steady state.
B) t½ 0.5 hr; requires continuous infusion.
C) t½ 17 hr; allows once-daily dosing.
D) t½ 35 hr; risk of accumulation with daily dosing.
Answer: A
Rationale: Half-life = 0.693 × Vd / Cl = 0.693 × 5 L / 1 L/hr "H 3.47 hr. A short half-life necessitates frequent dosing
to maintain therapeutic levels. Option B miscalculates (Cl/Vd), C and D use incorrect multipliers.
2 A novel drug is a weak base with pKa = 7.4. It is administered orally. Which of the following conditions would
MOST significantly enhance its absorption in the small intestine (pH 6.0)?
A) Concurrent administration of a proton pump inhibitor.
B) Formulation as a delayed-release enteric-coated tablet.
C) Coadministration with a high-fat meal that increases bile secretion.
D) Administration via sublingual route to avoid first-pass metabolism.
Answer: A
Rationale: At small intestinal pH 6.0, the drug (pKa 7.4) is predominantly ionized (weak base, pH < pKa). Raising
gastric pH with a PPI reduces ionization in the stomach but does not affect small intestine absorption; however, a
PPI increases gastric pH, which may reduce degradation and enhance dissolution. Option B delays release but not
absorption per se; C increases solubility of lipophilic drugs but not ionization-dependent absorption; D bypasses
first-pass but is not about absorption enhancement in the small intestine.
3 A drug follows Michaelis-Menten kinetics. At a dose of 100 mg, the steady-state concentration (Css) is 10
mg/L. When the dose is doubled to 200 mg, Css increases to 30 mg/L. Which of the following is the most likely
explanation?
A) The drug exhibits linear pharmacokinetics within this dose range.
B) The drug has a high extraction ratio and is flow-limited.
C) The drug's elimination pathway is saturable at the higher dose.
D) The drug's volume of distribution decreased due to dose-dependent protein binding.
Answer: C
Rationale: In Michaelis-Menten kinetics, when the dose approaches or exceeds the enzyme capacity (Km), Css
increases more than proportionally. Here, doubling the dose triples Css, indicating saturation. Option A is incorrect
because linear kinetics would show proportional increase; B is unrelated; D could cause a decrease in Vd but would
increase Css less than proportionally if binding is saturable, not more.
4 Which of the following best explains why a drug that is a substrate of CYP3A4 and P-glycoprotein (P-gp)
exhibits higher oral bioavailability when coadministered with grapefruit juice?
A) Grapefruit juice increases gastric pH, enhancing dissolution.
,B) Grapefruit juice inhibits intestinal CYP3A4 and P-gp, reducing first-pass metabolism and efflux.
C) Grapefruit juice induces hepatic CYP3A4, increasing clearance.
D) Grapefruit juice chelates the drug, forming a more absorbable complex.
Answer: B
Rationale: Grapefruit juice irreversibly inhibits intestinal CYP3A4 and also inhibits P-gp, leading to increased
absorption and reduced first-pass metabolism, thus increasing oral bioavailability. Option A is false; C is opposite
(induction would decrease bioavailability); D is not a known mechanism.
5 Two drugs, A and B, are both agonists at the same receptor. Drug A has an EC50 of 10 nM and produces a
maximal response (Emax) of 80% of the tissue maximum. Drug B has an EC50 of 100 nM and an Emax of
100%. Which of the following statements is correct?
A) Drug A is more potent and more efficacious than Drug B.
B) Drug A is more potent but less efficacious than Drug B.
C) Drug B is more potent and more efficacious than Drug A.
D) Drug B is more potent but less efficacious than Drug A.
Answer: B
Rationale: Potency is inversely related to EC50: lower EC50 = higher potency. Drug A (EC50=10 nM) is more
potent than Drug B (100 nM). Efficacy refers to maximal response: Drug B produces 100% (full agonist) vs Drug
A produces 80% (partial agonist). Thus A is more potent but less efficacious.
6 A drug is 99% bound to plasma albumin. Which of the following scenarios would MOST significantly increase
the free (unbound) fraction of the drug?
A) Hypoalbuminemia (albumin concentration reduced by 50%).
B) Coadministration with another drug that is 99% bound to albumin and has the same binding site.
C) Renal impairment that reduces drug clearance.
D) Hepatic enzyme induction increasing drug metabolism.
Answer: B
Rationale: Displacement from binding sites by a competing drug can significantly increase free fraction even with
normal albumin levels. Option A (hypoalbuminemia) reduces total binding capacity but for a highly bound drug
(99%), a 50% reduction in albumin might only increase free fraction from 1% to ~2% (still small). B can cause a
larger relative increase if the competitor has high affinity and concentration. C and D affect total drug concentration
but not directly binding fraction.
7 A drug has a low extraction ratio (E < 0.3) and is primarily eliminated by hepatic metabolism. Which of the
following best describes the effect of a decrease in hepatic blood flow on its clearance and half-life?
A) Clearance decreases, half-life increases.
B) Clearance unchanged, half-life unchanged.
C) Clearance increases, half-life decreases.
D) Clearance decreases, half-life unchanged.
Answer: B
Rationale: For low extraction ratio drugs, clearance is primarily dependent on intrinsic clearance (enzyme activity)
and protein binding, not hepatic blood flow. Therefore, a decrease in blood flow does not significantly alter
clearance. Half-life (t½ = 0.693 × Vd/Cl) remains unchanged if Cl and Vd are unchanged. Options A, C, D
incorrectly assume flow-dependence.
, 8 A drug follows a two-compartment model. After an IV bolus, the plasma concentration-time curve shows a
rapid initial decline ( phase) followed by a slower terminal phase ( phase). Which of the following parameters is
MOST directly associated with the phase half-life?
A) Distribution clearance (ClD)
B) Volume of the central compartment (Vc)
C) Elimination clearance (ClE) and volume of distribution at steady state (Vss)
D) Absorption rate constant (ka)
Answer: C
Rationale: In a two-compartment model, the terminal (²) half-life is determined by elimination clearance and the
overall volume of distribution (Vss or V). The phase reflects distribution. Option A relates to intercompartmental
clearance; B is part of distribution; D is irrelevant for IV bolus.
9 A drug is a weak acid with pKa = 4.4. Which of the following statements about its renal excretion is correct?
A) At urine pH 5.0, the drug is predominantly ionized and will be reabsorbed.
B) At urine pH 8.0, the drug is predominantly ionized and will be excreted more rapidly.
C) Alkalinization of urine will decrease the rate of excretion.
D) Acidification of urine will increase the rate of excretion.
Answer: B
Rationale: Weak acids are more ionized in alkaline pH (pH > pKa). At pH 8.0, the drug (pKa 4.4) is >99.9%
ionized, reducing reabsorption and enhancing excretion. Option A is incorrect because at pH 5.0 (below pKa), it is
mostly unionized and reabsorbed. C is opposite (alkalinization increases excretion). D is opposite (acidification
decreases excretion).
10 A drug has a therapeutic index (TI) of 2. Which of the following interpretations is correct?
A) The drug is safe with a wide margin between effective and toxic doses.
B) The median toxic dose (TD50) is twice the median effective dose (ED50).
C) The ED50 is twice the TD50.
D) The drug requires therapeutic drug monitoring due to narrow safety margin.
Answer: B
Rationale: Therapeutic index = TD50/ED50. A TI of 2 means the toxic dose is only twice the effective dose,
indicating a narrow margin. Option A is false (wide margin would be >10). C is reversed. D is a reasonable clinical
implication but not the direct definition; the question asks for interpretation of the numerical value, so B is the
precise definition.
Section 2: Autonomic Nervous System Drugs (Questions 11-25)
11 A patient with a history of hypertension and benign prostatic hyperplasia is prescribed tamsulosin. Which
receptor selectivity best explains the therapeutic effect on urinary symptoms while minimizing impact on blood
pressure?
A) Selective 1A-adrenoceptor antagonism
B) Selective 1B-adrenoceptor antagonism
C) Nonselective 1-adrenoceptor antagonism
D) 2-adrenoceptor agonism
Answer: A
Rationale: Tamsulosin is selective for ±1A-adrenoceptors, which predominate in the prostate and bladder neck,
allowing relief of urinary obstruction with less effect on vascular 1B-receptors, thus minimizing hypotension.
